Voyager Therapeutics

VYGR Rare disease Lead: Phase 1 8 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-09

Catalyst timeline

NBIB-'223 Friedreich's ataxia trial start2026NBIB-'223 Friedreich's ataxia trial start, 2026, routine
VY7523 interim4Q 2026VY7523 interim, 4Q 2026, major
VY1706 trial start4Q 2026VY1706 trial start, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

VY1706

Gene Therapy Target: tau mRNA, tau, MAPT

Alzheimer's Disease Preclinical intravenous NCT07764146

VY7523

Protein Target: tau

Alzheimer's Disease Phase 1 intravenous NCT06874621

frataxin gene therapy

NBIB-'223

Gene Therapy Target: FXN

Friedreich's Ataxia Preclinical intravenous Neurocrine Biosciences

glucosylceramidase beta 1 gene therapy

Gene Therapy Target: GBA1

Gaucher Disease Preclinical intravenous Neurocrine Biosciences
Parkinson's Disease Preclinical intravenous Neurocrine Biosciences

TDP-43 targeting small molecule

Small Molecule Target: TDP-43

Amyotrophic Lateral Sclerosis Preclinical Transition Bio
Frontotemporal Dementia Preclinical Transition Bio

selective small molecules

Small Molecule Target: TDP-43

Amyotrophic Lateral Sclerosis Preclinical Transition Bio
Frontotemporal Dementia Preclinical Transition Bio

Technology platforms

TRACER

Tropism Redirection of AAV by Cell-type-specific Expression of RNA — RNA-based AAV capsid discovery platform enabling rapid discovery of capsids with robust BBB penetration and enhanced CNS tropism in multiple species including NHPs; used to generate novel capsids for intravenously delivered AAV gene therapies targeting neurological diseases including Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, SMA, and Huntington's disease.

Targets: ALPL, ApoE4, ApoE2

Voyager NeuroShuttle

Non-viral delivery platform leveraging novel receptor-binding molecules (initially ALPL receptor) to transport multiple modalities of neurotherapeutics across the blood-brain barrier; early discovery stage targeting undisclosed neurological disease; demonstrated sustained brain expression over three weeks in murine proof-of-concept studies.

Targets: ALPL

Biotech Distilled coverage (8)

2026-08-07 UPDATE: Voyager Therapeutics (VYGR) - The Catalysts Slide Into Q4 🔒 Paid
2026-06-10 UPDATE: Voyager Therapeutics (VYGR) - The War-Chest Vote Passes
2026-06-02 UPDATE: Voyager Therapeutics (VYGR) - The IND Lands
2026-05-16 UPDATE: Voyager Therapeutics (VYGR) - EcoR1 Walks 🔒 Paid
2026-05-14 UPDATE: Voyager Therapeutics (VYGR) - The AAV Liver Ghost Got Quieter 🔒 Paid
2026-05-08 UPDATE: Voyager Therapeutics (VYGR) - The Q1 Print Answers Two Open Questions 🔒 Paid
2026-04-27 UPDATE: Voyager Therapeutics (VYGR) - The Second C-Suite Exit and the 240M-Share Tell 🔒 Paid
2026-03-17 Voyager Therapeutics (VYGR) - Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.